Faes Farma : Investor day highlights. Dull FY 2024 outlook
>FY 2024 likely to be, yet another, transition year with limited earnings growth - FY 2023 was a record year in terms of earnings, but total shareholder return was negative (-5%). The year was marked by post-patent decline in Europe of its key product Bilastine and weak trends for its animal health unit (sales -17% in Q4 2023), impacted by the lower swine livestock in Europe because of the swine flu, factors that were offset by market expansion in LatAm and the resi...Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.